NCT04622592View on ClinicalTrials.gov

Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

209

Participants

Timeline

Start Date

November 2, 2020

Primary Completion Date

April 26, 2022

Study Completion Date

April 26, 2022

Conditions
Influenza
Interventions
BIOLOGICAL

Instramuscular vaccine

On Day 0, a single injection of the assigned dose of the vaccine into the deltoid region of the arm

Trial Locations (14)

20850

Optimal Sites, Rockville

29204

Vitalink Research, Columbia

29340

Vitalink Research, Gaffney

29379

Vitalink Research, Union

29621

Vitalink Research, Anderson

32806

Global AES, Orlando

61614

Optimal Sites, Peoria

85224

Synexus, Chandler

92108

Optimal Sites, San Diego

35802-2569

Optimal Sites, Huntsville

32934-8172

Optimal Sites, Melbourne

32162-7116

Global AES, The Villages

47714-7513

Synexus, Evansville

78705-2655

Optimal Sites, Austin

Sponsors

Lead Sponsor

Medicago
All Listed Sponsors
lead

Medicago

INDUSTRY

NCT04622592 - Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older | Biotech Hunter | Biotech Hunter